Prospects for new plague vaccines

References

• Achtman M, Zurth K, Morelli C, Torrea G, Guiyoule A, Carniel E. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl Acad. Sci. USA96, 14043–14048 (1999).
   PubMed Web of Science ®Google Scholar
• Perry RD, Fetherston JD. Yersinia pestis – etiologic agent of plague. Clin. Microbiol. Rev.10(1), 35–66 (1997).
   PubMed Web of Science ®Google Scholar
• Prevention of plague. Recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR45(14), 1–15 (1996).
   PubMedGoogle Scholar
• Pollitzer R. Plague. WHO, Geneva, Switzerland (Monograph series) (1954).
   Google Scholar
• Stenseth NC, Atshabar BB, Begon M et al. Plague: past, present, and future. PLoS Med.5(1), e3– (2008).
   PubMed Web of Science ®Google Scholar
• Alibek K, Handelman S. Biohazard. Random House, NY, USA (1999).
   Google Scholar
• Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon. JAMA283(17), 2281–2290 (2000).
   PubMed Web of Science ®Google Scholar
• Nikolaev NI. Plague (Clinical, Diagnostic, Treatment and Prophylaxis Aspects). Meditcina, Moscow, USSR (1968).
   Google Scholar
• USAMRIID’s Medical Management of Biological Casualties Handbook (4th Edition). Kortepeter M, Christopher G, Cieslak T et al. (Eds). US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA, 2–31 (2001).
   Google Scholar
• Smiley ST. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines7(2), 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Titball RW, Leary SE. Plague. Br. Med. Bull.54(3), 625–633 (1998).
   PubMedGoogle Scholar
• Butler T. Yersinia species (including plague). In: Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin E (Eds). Churchill Livingstone, NY, USA, 2070–2078 (1995).
   Google Scholar
• Feodorova VA, Devdariani ZL. The interaction of Yersinia pestis with erythrocytes. J. Med. Microbiol.51, 150–158 (2002).
   PubMed Web of Science ®Google Scholar
• Chain PS, Carniel E, Larimer FW et al. Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc. Natl Acad. Sci. USA101, 13826–13831 (2004).
   PubMed Web of Science ®Google Scholar
• Anisimov AP, Lindler LE, Pier GB. Intraspecific diversity of Yersinia pestis. Clin. Microbiol. Rev.17, 434–464 (2004).
   PubMed Web of Science ®Google Scholar
• Aikimbajev A, Meka-Mechenko T, Temiralieva G et al. Plague in Kazakhstan at the present time. Przegl. Epidemiol.57(4), 593–598 (2003).
   PubMedGoogle Scholar
• Cleri DJ, Vernaleo JR, Lombardi LJ et al. Plague pneumonia disease caused by Yersinia pestis. Semin. Respir. Infect.12(1), 12–23 (1997).
   PubMedGoogle Scholar
• Keeling MJ, Gilligan CA. Metapopulation dynamics of bubonic plague. Nature407, 903–906 (2000).
   PubMed Web of Science ®Google Scholar
• Galimand M, Guiyoule AN, Gerbaud G et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med.337(10), 677–680 (1997).
   PubMed Web of Science ®Google Scholar
• Deng W, Burland V, Plunkett G et al. Genome sequence of Yersinia pestis KIM. J. Bacteriol.84(16), 4601–4611 (2002).
   Google Scholar
• Parkhill J, Wren BW, Thomson NR et al. Genome sequence of Yersinia pestis, the causative agent of plague. Nature413, 523–527 (2001).
   PubMed Web of Science ®Google Scholar
• Buchrieser C, Prentice M, Carniel E. The 102-kilobase unstable region of Yersinia pestis comprises a high-pathogenicity island linked to a pigmentation segment which undergoes internal rearrangement. J. Bacteriol.180, 2321–2329 (1998).
   PubMed Web of Science ®Google Scholar
• Buchrieser C, Rusniok C, Frangeul L et al. The 102-kilobase pgm locus of Yersinia pestis : sequence analysis and comparison of selected regions among different Yersinia pestis and Yersinia pseudotuberculosis strains. Infect. Immun.67, 4851–4861 (1999).
   PubMed Web of Science ®Google Scholar
• Cornelis G. The Yersinia YSC – Yop ‘type III’ weaponry. Nat. Rev.2, 742–752 (2002).
   Google Scholar
• Cornelis G, Boland A, Boyd AP et al. The virulence plasmid of Yersinia, an antihost genome. Microbiol. Mol. Biol. Rev.62, 1315–1352 (1998).
   PubMed Web of Science ®Google Scholar
• Fetherston JD, Perry RD. The pigmentation locus of Yersinia pestis KIM6+ is flanked by an insertion sequence and includes the structural genes for pesticin sensitivity and HMWP2. Mol. Microbiol.13, 697–708 (1994).
   PubMed Web of Science ®Google Scholar
• Tong Z, Zhou D, Song Y et al. Pseudogene accumulation might promote the adaptive microevolution of Yersinia pestis. J. Med. Microbiol.54(3), 259–268 (2005).
   PubMed Web of Science ®Google Scholar
• Balakhonov SV. Detection of pla, pst1 and caf1 gene nucleotide sequences on cryptic plasmid 33 kb of Yersinia pestis strains from tuva plague focus. In: Proceeding of 8th International Symposium on Yersinia. Turku, Finland, 4–8 September 2002, 78–79, P-64 (2002).
   Google Scholar
• Portnoy DA, Martinez RJ. Role of a plasmid in the pathogenicity of Yersinia species. Curr. Top. Microbiol. Immunol.118, 29–51 (1985).
   PubMed Web of Science ®Google Scholar
• Friedlander AM, Welkos SL, Worsham PL et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin. Infect. Dis.21, 178–181 (1995).
   PubMed Web of Science ®Google Scholar
• Du Y, Rosqvist R, Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect. Immun.70, 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Galyov EE, Smirnov OY, Karlishev AV et al. Nucleotide sequence of the Yersinia pestis gene encoding FI antigen and the primary structure of the protein. Putative T and B cell epitopes. FEBS Lett.277, 230–232 (1990).
   PubMed Web of Science ®Google Scholar
• Grosfeld H, Cohen S, Bino T et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect. Immun.71, 374–383 (2003).
   PubMed Web of Science ®Google Scholar
• Titball RW, Howells AM, Oyston PC, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun.65, 1926–1930 (1997).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Devdariani ZL. New genes involved in Yersinia pestis fraction I biosynthesis. J. Med. Microbiol.50, 969–978 (2001).
   PubMed Web of Science ®Google Scholar
• Basova NN, Kravtsov FE, Naumovich LS. Monthly dynamics of the antitoxic immunity against diphtheria and tetanus and of normal antibodies to fraction I of the plague microbe in adults. Zh. Mikrobiol.3, 82–86 (1982).
   Google Scholar
• Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull. WHO42(5), 653–666 (1970).
   PubMed Web of Science ®Google Scholar
• Pautov VN, Chicherin YuV, Evstigneev VI, Byvalov AA, Kedrov OA. Experimental protective activity of fraction I of the plague microbe. Zh. Mikrobiol.10, 37–42 (1979).
   Google Scholar
• Devdariani ZL, Fedorova VA, Gromova OV, Taranenko TM. Comparative incidence of detection of specific antibodies to Yersinia pestis capsular antigen and lipopolysaccharide in humans immunized with pest vaccine. Klin. Lab. Diagn.4, 39–41 (1997).
   Google Scholar
• Meyer KF. Serological tests for the confirmation of plague infections: a preliminary communication. Bull. WHO30, 750–751 (1964).
   PubMedGoogle Scholar
• Benner GE, Andrews GP, Russel W et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infect. Immun.67, 1922–1928 (1999).
   PubMed Web of Science ®Google Scholar
• Rudolph AE, Stuckey JA, Zhao Y et al. Expression, characterization amd mutagenesis of the Yersinia pestis murine toxin, a phospholipase D superfamily member. J. Biol. Chem.274, 11824–11831 (1999).
   PubMed Web of Science ®Google Scholar
• Hinnebusch J, Cherepanov P, Du Y et al. Murine toxin of Yersinia pestis shows phospholipase D activity but is not required for virulence in mice. Int. J. Med. Microbiol.290, 483–487 (2000).
   PubMed Web of Science ®Google Scholar
• Sinichkina NA, Kravtsov AL, Naumov AV, Kuzmichenko IA, Taranenko TM, Zadumina S. Comparative cytofluorometric analysis of leukocytes in the blood of guinea pigs under the action of Yersinia pestis phospholipase D and some Y. pestis antigens. Zh. Microbiol.11–12, 52–54 (1992).
   Google Scholar
• Feodorova VA, Golova AB. Antigenic and phenotypic modifications of Yersinia pestis in conditions simulating mammalian bloodstream. J. Med. Microbiol.54, 435–441 (2005).
   PubMed Web of Science ®Google Scholar
• Chicherin IuV, Evstigneev VI, Lebedinskii VA. Duration and intensity of postvaccinal immunity to plague in experimental animals. Zh. Mikrobiol.5, 95–98 (1977).
   Google Scholar
• Smith PN. Pneumonic plague in mice: modification of the infection by antibody against specific components of Pasteurella pestis. J. Infect. Dis.104(1), 85–91 (1959).
   PubMed Web of Science ®Google Scholar
• Hinnebusch BJ, Rudolph AE, Cherepanov P, Dixon JE, Schwan TG, Forsberg A. Role of Yersinia murine toxin in survival of Yersinia pestis in the midgut of the flea vector. Science296, 733–735 (2002).
   PubMed Web of Science ®Google Scholar
• Sodeinde OA, Goguen JD. Genetic analysis of the 9.5-kilobase virulence plasmid of Yersinia pestis. Infect. Immun.56, 2743–2748 (1988).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Devdariani ZL. Development, characterization and diagnostic application of monoclonal antibodies against Yersinia pestis fibrinolysin and coagulase. J. Med. Microbiol.49, 261–269 (2000).
   PubMed Web of Science ®Google Scholar
• McDonough KA, Falkow S. A Yersinia pestis-specific DNA fragment encodes temperature-dependent coagulase and fibrinolysin-associated phenotypes. Mol. Microbiol.3, 767–775 (1989).
   PubMed Web of Science ®Google Scholar
• Kukkonen M, Korhonen TK. The Omptin family of enterobacterial surface protease/adhesins: from housekeeping in Escherichia coli to systemic spread of Yersinia pestis. J. Med. Microbiol.294, 7–14 (2004).
   Web of Science ®Google Scholar
• Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiol. Rev.25, 531–552 (2001).
   PubMed Web of Science ®Google Scholar
• Easterbrook TJ, Reddin K, Robinson A, Modi N. Studies on the immunogenicity of the Pla protein from Yersinia pestis. Contrib. Microbiol. Immunol.13, 214–215 (1995).
   PubMedGoogle Scholar
• Welkos S, Pitt MLM, Martinez M, Friedlander A, Vogel P, Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine20, 2206–2214 (2002).
   PubMed Web of Science ®Google Scholar
• Sodeinde OA, Subrahmanian YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science258, 1004–1007 (1992).
   PubMed Web of Science ®Google Scholar
• Wang S, Joshi S, Mboudjeka I et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/c mice. Vaccine26, 1664–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Broz P, Mueller CA, Muller SA et al. Function and molecular architecture of the Yersinia injectisome tip complex. Mol. Microbiol.65, 1311–1320 (2007).
   PubMed Web of Science ®Google Scholar
• Leary SE, Griffin KF, Galyov EE et al.Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb. Pathog.26, 159–169 (1999).
   PubMed Web of Science ®Google Scholar
• Brubaker RR. Interleukin-10 and inhibition of innate immunity to Yersiniae : roles of Yops and LcrV (V antigen). Infect. Immun.71, 3673–3681 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson GW, Leary SEC, Williamson ED et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect. Immun.64, 4580–4585 (1996).
   PubMed Web of Science ®Google Scholar
• Pullen JK, Anderson GW, Welkos SL, Friedlander AM. Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes. Infect. Immun.66, 521–527 (1998).
   PubMed Web of Science ®Google Scholar
• Hill J, Leary SEC, Griffin KF, Williamson ED, Titball RW. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect. Immun.65, 4476–4482 (1997).
   PubMed Web of Science ®Google Scholar
• Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to Yersiniae mediated by anti-recombinant V antigen and protein A–V antigen fusion peptide. Infect. Immun.62, 4192–4201 (1994).
   PubMed Web of Science ®Google Scholar
• Cornelius CA, Quenee LE, Overheim KA et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect. Immun.76(12), 5588–5597 (2008).
   PubMed Web of Science ®Google Scholar
• Vernazza C, Lingard B, Flick-Smith HC, Baillie LW, Hill J, Atkins HS. Small protective fragments of the Yersinia pestis V antigen. Vaccine27(21), 2775–2780 (2009).
   PubMed Web of Science ®Google Scholar
• Schmidt A, Schaffelhofer S, Müller K, Röllinghoff M, Beuscher HU. Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity. Microb. Pathog.26(4), 221–233 (1999).
   PubMed Web of Science ®Google Scholar
• Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesmann J. Passive immunity to infection with Yersinia spp. mediated by polymorphism of V antigen. Infect. Immun.65, 446–451 (1997).
   PubMed Web of Science ®Google Scholar
• Anisimov AP, Panfertsev EA, Svetoch TE, Dentovskaya SV. Variability of the protein sequences of lcrV between epidemic and atypical rhamnose-positive strains of Yersinia pestis. Adv. Exp. Med. Biol.603, 23–27 (2007).
   PubMed Web of Science ®Google Scholar
• Andrews GP, Strachan ST, Benner GE et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect. Immun.67, 1533–1537 (1999).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Devdariani ZL. Immunogenicity and structural organization of some pLCR-encoded proteins of Yersinia pestis. J. Med. Microbiol.50, 13–22 (2001).
   PubMed Web of Science ®Google Scholar
• Russmann H. Yersinia outer protein E, YopE. A versatile type III effector molecule for cytosolic targeting of heterologous antigens by attenuated Salmonella. Adv. Exp. Med. Biol.529, 407–413 (2003).
   PubMed Web of Science ®Google Scholar
• Ivanov MI, Noel BL, Rampersaud R, Mena P, Benach JL, Bliska JB. Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1-Yersinia pestis. Infect. Immun.76, 5181–5190 (2008).
   PubMed Web of Science ®Google Scholar
• Burrows TW. Virulence of Pasteurella pestis. Nature179, 1246–1247 (1957).
   PubMed Web of Science ®Google Scholar
• Burrows TW, Bacon GA. The basis of virulence in Pasteurella pestis : an antigen determining virulence. Br. J. Exp. Pathol.37, 481–493 (1956).
   PubMedGoogle Scholar
• Michel P, Rasoamanana B, Rasolofonirina N, Roux J. The plague: disease and vaccine? Dakar Med.37, 183–189 (1992).
   PubMedGoogle Scholar
• Ben-Efraim S, Aronson M, Bichowsky-Slomnicki L. New antigenic component of Pasteurella pestis formed under specific conditions of pH and temperature. J. Bacteriol.81, 704–714 (1961).
   PubMed Web of Science ®Google Scholar
• Lindler LE, Klempner MS, Straley SC. Yersinia pestis pH 6 antigen: genetic, biochemical, and virulence characterization of a protein involved in the pathogenesis of bubonic plague. Infect. Immun.58(8), 2569–2577 (1990).
   PubMed Web of Science ®Google Scholar
• Tores-Escobar A, Juarez-Rodriguez MD, Curtiss R. III. Biogenesis of Yersinia pestis PsaA and its expression in recombinant attenuated Salmonella typhimurium vaccine (RASV) strains. FEMS Microbiol. Lett. (2009) (Epub ahead of print).
   Google Scholar
• Zav’yalov VP, Abramov VM, Cherepanov PG et al. pH6 antigen (PsaA protein) of Yersinia pestis, a novel bacterial Fc-receptor. FEMS Immunol. Med. Microbiol.14(1), 53–57 (1996).
   PubMed Web of Science ®Google Scholar
• Cathelyn JS, Crosby SD, Lathem WW, Goldman WE, Miller VL. RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague. Proc. Natl Acad. Sci. USA103(36), 13514–13519 (2006).
   PubMed Web of Science ®Google Scholar
• Anisimov AP, Bakhteeva IV, Panfertsev EA et al. The subcutaneous inoculation of pH 6 antigen mutants of Yersinia pestis does not affect virulence and immune response in mice. J. Med. Microbiol.58, 26–36 (2009).
   PubMed Web of Science ®Google Scholar
• Prior JL, Parkhill J, Hitchen PG et al. The failure of different strains of Yersinia pestis to produce lipopolysaccharide O-antigen under different growth conditions is due to mutations in the O-antigen gene cluster. FEMS Microbiol. Lett.197, 229–233 (2001).
   PubMed Web of Science ®Google Scholar
• Vinogradov EV, Lindner B, Kocharova NA et al. Core structure in the lipopolysaccharide of the causative agent of plague, Yersinia pestis. Carbohydr. Res.337, 775–777 (2002).
   PubMed Web of Science ®Google Scholar
• Bruneteau M, Minka S. Lipopolysaccharides of bacterial pathogens from the genus Yersinia : a mini-review. Biochemistry85, 145–152 (2003).
   Google Scholar
• Vinogradov EV, Knirel YuA, Thomas-Oates JE, Shashkov AS, L’vov VL. The structure of the cyclic enterobacterial common antigen (ECA) from Yersinia pestis. Carbohydr. Res.258, 223–232 (1994).
   PubMed Web of Science ®Google Scholar
• Skurnik M, Bengoechea JA. The biosynthesis and biological role of lipopolysaccharide O-antigens of pathogenic Yersiniae. Carbohydr. Res.338, 2521–2529 (2003).
   PubMed Web of Science ®Google Scholar
• Karlyshev AV, Oyston PCF, Williams K et al. Application of high-density array-based signature-tagged mutagenesis to discover novel Yersinia virulence-associated genes. Infect. Immun.69, 7810–7819 (2001).
   PubMed Web of Science ®Google Scholar
• Dodgson C, Amor P, Whitfield C. Distribution of the rol gene encoding the regulator of lipopolysaccharide O-chain length in Escherichia coli and its influence on the expression of group I capsular K antigens. J. Bacteriol.178, 1895–1902 (1996).
   PubMed Web of Science ®Google Scholar
• Feodorova VA. Theoretical and experimental aspects of the study of protein and carbohydrate antigens of Yersinia pestis and Vibrio cholerae O139 using polyclonal and monoclonal antibodies. D. Sci. Thesis, Saratov, Russia (2004).
   Google Scholar
• Prior JL, Hitchen PG, Williamson ED et al. Characterization of the lipopolysaccharide of Yersinia pestis. Microb. Pathog.30, 49–57 (2001).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Devdariani ZL, Nazarova LS. Adjuvant effect of anti-idiotypic antibodies to Yersinia pestis lipopolysaccharide. J. Med. Microbiol.48, 751–756 (1999).
   PubMed Web of Science ®Google Scholar
• Hitchen PG, Prior JL, Oyston PCF et al. Structural characterization of lipo-oligosaccharide (LOS) from Yersinia pestis : regulation of LOS structure by the PhoPQ system. Mol. Microbiol.44, 1637–1650 (2002).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Devdariani ZL. Expession of acid-stable proteins and modified lipopolysaccharide of Yersinia pestis in acidic growth medium. J. Med. Microbiol.50, 979–985 (2001).
   PubMed Web of Science ®Google Scholar
• Gremyakova TA, Vinogradov EV, Lindner B et al. The core structure of the lipopolysaccharide of Yersinia pestis strain KM218. Adv. Exp. Med. Biol.529, 229–231 (2003).
   PubMed Web of Science ®Google Scholar
• Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun.70, 4092–4098 (2002).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Pan’kina LN, Savostiva EP et al. Pleiotropic effects of the lpx mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens. Vaccine27(16), 2240–2250 (2009).
   PubMed Web of Science ®Google Scholar
• Montminy SW, Khan N, Mc Grath S et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol.7(10), 1066–1073 (2006).
   PubMed Web of Science ®Google Scholar
• Fetherston JD, Schuetze P, Perry RD. Loss of the pigmentation phenotype in Yersinia pestis is due to the spontaneous deletion of 102 kb of chromosomal DNA which is flanked by a repetitive element. Mol. Microbiol.6, 2693–2704 (1992).
   PubMed Web of Science ®Google Scholar
• Brubaker RR. Mutation rate to non pigmentation in Pasteurella pestis. J. Bacteriol.98, 1404–1406 (1969).
   PubMed Web of Science ®Google Scholar
• Flasher Y, Mamround E, Tidhar Aet al. Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect. Immun.72, 908–1015 (2004).
   PubMed Web of Science ®Google Scholar
• Fournier J, Paul G, Chomel J, Dodin A, Fontanges R. Experimental study of subcutaneous and aerosol vaccination against the plague in cynocephalous monkeys. Absence of correlation between hemagglutination and precipitant antibodies and protection. Ann. Microbiol. (Paris)124, 315–328 (1973).
   PubMedGoogle Scholar
• Kutyrev VV, Filippov AA, Oparina OS, Protsenko OA. Analysis of Yersinia pestis chromosomal determinants Pgm+ and Psts associated with virulence. Microb. Pathog.12, 177–186 (1992).
   PubMed Web of Science ®Google Scholar
• Kutyrev VV, Filippov AA, Oparina OS, Protsenko OA. Genetic analysis and modeling of the virulence of Yersinia pestis. Mol. Genet. Microbiol. Virusol.8, 42–47 (1989).
   Google Scholar
• Saltykova RA, Faibich MM. Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR. Zh. Mikrobiol.6, 3–8 (1975).
   Google Scholar
• Byvalov AA, Pautov VN, Chicherin YV et al. Effectiveness of the revaccination of Hamadryas baboons with dried live plague vaccine NIIS and Yersinia pestis fraction 1. Zh. Microbiol.4, 74–76 (1984).
   Google Scholar
• Hallett AF, Issacson M, Meyer KF. Pathogenicity and immunogenic efficacy of a live attenuated plague vaccine in vervet monkeys. Infect. Immun.8, 876–881 (1973).
   PubMed Web of Science ®Google Scholar
• Iteman I, Guiyoule A, De Almeida AMP, Guilvout I, Baranton G, Carniel E. Relationship between loss of pigmentation and deletion of chromosomal iron-regulated irp2 gene in Yersinia pestis : evidence for separate but related events. Infect. Immun.61, 2717–2722 (1993).
   PubMed Web of Science ®Google Scholar
• Jarrett CO, Deak E, Isherwood KE et al. Transmission of Yersinia pestis from an infectious biofilm in the flea vector. J. Infect. Dis.190, 783–792 (2004).
   PubMed Web of Science ®Google Scholar
• Joshua GW, Karlyshev AV, Smith MP, Isherwood KE, Titball RW, Wren BW. A Caenorhabditis elegans model of Yersinia infection: biofilm formation on a biotic surface. Microbiology149, 3221–3229 (2003).
   PubMed Web of Science ®Google Scholar
• Kirillina O, Fetherston JD, Bobrov AG, Abney J, Perry RD. HmsP, a putative phosphodiesterase, and HmsT, a putative diguanylate cyclase, control Hms-dependent biofilm formation in Yersinia pestis. Mol. Microbiol.54, 75–88 (2004).
   PubMed Web of Science ®Google Scholar
• Bearden SW, Fetherston JD, Perry RD. Genetic organization of the yersiniabactin biosynthetic region and construction of avirulent mutants in Yersinia pestis. Infect. Immun.65, 1659–1668 (1997).
   PubMed Web of Science ®Google Scholar
• Isupov IV, Beloborodov RA. Experimental Pathomorphology After Application of Live Plague Vaccine EV NIIEG. Institute ‘Microbe’, Saratov, Russia (1995).
   Google Scholar
• Jackson S, Burrows TW. The virulence-enhancing effect of iron on non-pigmented mutants of virulent strains of Pasteurella pestis. Br. J. Exp. Pathol.37, 577–583 (1956).
   PubMedGoogle Scholar
• Lillard JW, Bearden SW, Fetherston JD, Perry RD. The haemin storage (Hms+) phenotype of Yersinia pestis is not essential for the pathogenesis of bubonic plague in mammals. Microbiology145, 197–209 (1999).
   PubMed Web of Science ®Google Scholar
• Bearden SW, Perry RD. The Yfe system of Yersinia pestis transports iron and manganese and is required for full virulence of plague. Mol. Microbiol.32, 403–414 (1999).
   PubMed Web of Science ®Google Scholar
• Robinson JB, Telepnev MV, Zudina IV et al. Evaluation of a Yersinia pestis mutant impaired in a thermoregulated type VI-like secretion system in flea, macrophage and murine models. Microb. Pathog.47(5), 243–251 (2009).
   PubMed Web of Science ®Google Scholar
• Oyston PC, Dorrell N, Williams K et al. The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis. Infect. Immun.68, 3419–3425 (2000).
   PubMed Web of Science ®Google Scholar
• Huang XZ, Lindler LE. The pH 6 antigen is an antiphagocytic factor produced by Yersinia pestis independent of Yersinia outer proteins and capsule antigen. Infect. Immun.72(12), 7212–7219 (2004).
   PubMed Web of Science ®Google Scholar
• Bullen JJ. The significance of iron in infection. Rev. Infect. Dis.3, 1127–1138 (1981).
   PubMedGoogle Scholar
• Ilyukhin VI, Plekhanova NG, Senina TV, Stanovaya OV, Kislichkin NN. Experimental evidence of the possibility of using live tularemia vaccine to increase resistance to heterologous infectious diseases. Zh. Microbiol.2, 38–42 (2004).
   Google Scholar
• Nazarova LS, Isupov IV, Samoilova LV, Piontkovskii SA, Ovsiannikov VI, Suchkova OP. The effect of multiple plague vaccination on immune system indices. Zh. Mikrobiol.6, 65–66 (1994).
   Google Scholar
• Oyston PCF, Russell P, Williamson E et al. An aroA mutant of Yersinia pestis is attenuated in the guinea pig but virulent in mice. Microbiology142, 1847–1853 (1995).
   Web of Science ®Google Scholar
• Lavrov VF. Mechanisms of development of immunological memory and vaccination. Epidemiol. Vaccinol.4, 39–41 (2004).
   Google Scholar
• Elvin SJ, Williamson ED, Scott JC et al. Evolutionary genetics: ambiguous role of CCR5 in Y. pestis infection. Nature430(6998), 417 (2004).
   PubMedGoogle Scholar
• Mecsas J, Franklin G, Kuziel WA, Brubaker RR, Falkow S, Mosier DE. Evolutionary genetics: CCR5 mutation and plague protection. Nature427(6975), 606 (2004).
   PubMed Web of Science ®Google Scholar
• Tollenaere C, Rahalison L, Ranjalahy M et al. CCR5 polymorphism and plague resistance in natural populations of the black rat in Madagascar. Infect. Genet. Evol.8(6), 891–897 (2008).
   PubMed Web of Science ®Google Scholar
• Quan SF, Chen TH, Meyer KF. Protective action of antibiotics against the toxin of Pasteurella pestis in mice. Proc. Soc. Exp. Biol. Med.75(2), 548–549 (1950).
   PubMed Web of Science ®Google Scholar
• Green M, Rogers D, Russell P et al. The SCID/beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol. Med. Microbiol.23(2), 107–113 (1999).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Flick-Smith HC, LeButt CS et al. Human immune response to a plague vaccine comprising recombinant F1 and rV antigens. Infect. Immun.73, 3598–3608 (2005).
   PubMed Web of Science ®Google Scholar
• Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin. Vaccine Immunol.14(5), 605–616 (2007).
   PubMedGoogle Scholar
• Englesberg E, Chen TH, Levy JB, Foster LE, Meyer KF. Virulence in Pasteurella pestis. Science119(3091), 413–414 (1954).
   PubMed Web of Science ®Google Scholar
• Elvin SJ, Williamson ED. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb. Pathog.37(4), 177–184 (2004).
   PubMed Web of Science ®Google Scholar
• Williams JE, Altieri PL, Berman S, Lowenthal JP, Cavanaugh DC. Potency of killed plague vaccines prepared from avirulent Yersinia pestis. Bull. WHO58(5), 753–756 (1980).
   PubMed Web of Science ®Google Scholar
• Meyer KF. The clinical and immunological response of man to P. pestis vaccine (summary and conclusions). Proceedings of:the Symposium on Bacterial Vaccines. The Yugoslav Academy of Science and Arts, Zagreb, Croatia (1971).
   Google Scholar
• Jones SM, Griffin KF, Williamson ED. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine21(25–26), 3912–3918 (2003).
   PubMed Web of Science ®Google Scholar
• Marshall JD. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis.129, 19–25 (1974).
   Google Scholar
• Haffkine WM, Bennermann WB. The testing of Haffkine’s plague prophylactic vaccine in plague stricken communities in India. Br. Med. J.1(6), 856–858 (1989).
   Google Scholar
• Meyer KF, Cavanaugh DC, Bartelloni PJ, Marshall JD. Plague immunization. I. Past and present trends. J. Infect. Dis.129, 13–18 (1974).
   Google Scholar
• Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine13(16), 1551–1556 (1995).
   PubMed Web of Science ®Google Scholar
• Strong RP. Studies in plague immunity. Philipp. J. Sci.2(3), 155–331 (1907).
   Google Scholar
• Otten L. Immunization against plague with live vaccine. Indian J. Med. Res.24(1), 73–101 (1936).
   Google Scholar
• Altaryova ND, Antonov AM, Zhdanov VM et al. Alive bivalent anti-plague vaccine 1–17 and intracutaneous method of vaccination. Proceedings of: Institute ‘Microbe’. Saratov, Russia, 68–122 (1958).
   Google Scholar
• Girard G. Immunity in plague infection. Results of 30 years of work with the Pasteurella pestis EV strain (Girard and Robic). Biol. Med. (Paris)52, 631–731 (1963).
   PubMedGoogle Scholar
• Anisimov PI, Anisimova TI, Aparin GP et al. Changes of Y. pestis EV vaccine strain properties after passages trough in the organisms of pikes. In: Problems of Particularly Dangerous Diseases. Saratov, Russia, 5, 68–74 (1969).
   Google Scholar
• Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin. Biol. Ther.4, 965–973 (2004).
   PubMed Web of Science ®Google Scholar
• Smirnov VP. Vaccination against plague via conjunctiva. Proc. Irk. Antiplague Inst. Suberia Far East (Irkutsk, USSR)24(2), 146–161 (1962).
   Google Scholar
• Pushkareva VI. Experimental evaluation of interactions between Yersinia pestis EV and soil infusoria and the possibility of the prolonged preservation of bacteria in the protozoa cysts. Zh. Microbiol.4, 40–44 (2003).
   Google Scholar
• Higuchi K, Smith JL. Studies on the nutrition and physiology of Pasteurella pestis. VI. A differential plating medium for the estimation of the mutation rate to avirulence. J. Bacteriol.81, 605–608 (1961).
   PubMed Web of Science ®Google Scholar
• Semenova YeL. Influence of organism of the plague-resistant animals upon the Y. pestis virulence. Proc. Asian Res. Antiplague Inst. Alma-Ata4, 129–134 (1958).
   Google Scholar
• Derteva II. Influence of the antiplague sera upon Y. pestisin vitro and in biomodels. Proceedings of:the Institute ‘Microbe’. Saratov, Russia, 2, 46–53 (1958)
   Google Scholar
• Donskov GD, Lokhov MG. Influence of ethanol upon morphological, biochemical and biological properties of B. pestis. Vestnik Microbiol. Epidemiol. Parasitol.15, 187–194 (1936).
   Google Scholar
• Malinina ZYe. Selection of vaccine strains during in vitro cultivation with streptomycin. In: Particularly Dangerous and Natural Focal Infections. Meditcina, Moscow, USSR, 114–119 (1962).
   Google Scholar
• Akimovich VV, Nikolaev NI, Zykin LF, Ponomaryov NG, Popov AA. Application of the Jackson-Burrows’s and Higuchi-Smith’s media for selection of Yersinia pestis strains with different level of virulence. In: Microbiology and Laboratory Diagnostics of Particularly Dangerous Disease. Saratov, Russia, 44–50 (1965).
   Google Scholar
• Williams K, Oyston PC et al. Investigation into the role of the serine protease Htr in Yersinia pestis pathogenesis. FEMS Microbiol. Lett.186, 281–286 (2005).
   Google Scholar
• Sha J, Agar SL, Baze WB et al. Braun lipoprotein (Lpp) contributes to virulence of Yersiniae : potential role of Lpp in inducing bubonic and pneumonic plague. Infect. Immun.76, 1390–1409 (2008).
   PubMed Web of Science ®Google Scholar
• Szaba FM, Kummer LW, Wilhelm LB et al. D27-pLpxL, an avirulent strain of Yersiniapestis, primes T cells that protect against pneumonic plague. Infect. Immun.77(10), 4295–4304 (2009).
   PubMed Web of Science ®Google Scholar
• Garmory HS, Griffin KF, Brown KA, Titball RW. Oral immunization with live aroA Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine21, 3051–3057 (2003).
   PubMed Web of Science ®Google Scholar
• Garmory HS, Leary SE, Griffin KF, Williamson ED, Brown KA, Titball RW. The use of live attenuated bacteria as a delivery system for heterologous antigens. J. Drug Target.11, 471–479 (2003).
   PubMed Web of Science ®Google Scholar
• Osorio JE, Powell TD, Frank RS et al. Recombinant raccoon pox vaccine protects mice against lethal plague. Vaccine21, 1232–1238 (2003).
   PubMed Web of Science ®Google Scholar
• Sofer-Podesta C, Ang J, Hackett NR et al. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect. Immun.77, 1561–1568 (2009).
   PubMed Web of Science ®Google Scholar
• Palin A, Chattopadhyay A, Park S et al. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine25, 741–750 (2007).
   PubMed Web of Science ®Google Scholar
• Alvarez ML, Pinyerd HL, Crisantes JD et al. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine24, 2477–2490 (2006).
   PubMed Web of Science ®Google Scholar
• Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect. Immun.76(8), 3640–3650 (2008).
   PubMed Web of Science ®Google Scholar
• Del Prete G, Santi L, Andrianaivoarimanana V et al. Plant-derived recombinant F1, V, and F1-V fusion antigens of Yersinia pestis activate human cells of the innate and adaptive immune system. Int. J. Immunopathol. Pharmacol.22, 133–143 (2009).
   PubMed Web of Science ®Google Scholar
• Mizel SB, Graff AH, Sriranganathan N et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin. Vaccine Immunol.16, 21–28 (2009).
   PubMed Web of Science ®Google Scholar
• Alonso JM. Ecological interaction among Yersinia in their common reservoir, the rodent. Bull. Soc. Pathol. Exot.92, 414–417 (1999).
   PubMed Web of Science ®Google Scholar
• Ellis J, Oyston PCF, Green M, Titball RW. Tularemia. Clin. Microbiol. Rev.15, 631–646 (2002).
   PubMed Web of Science ®Google Scholar
• Williamson ED. Plague vaccine research and development. J. Appl. Microbiol.91(4) (2001).
   PubMedGoogle Scholar
• Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol.12(3–4), 223–230 (1995).
   PubMedGoogle Scholar
• Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M, Titball RW. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin. Exp. Immunol.116, 107–114 (1999).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Spier ID, Stagg AJ, Jones SM, Alpar HO. Generation of protective immune response to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J. Control. Release63, 191–200 (2000).
   PubMed Web of Science ®Google Scholar
• Eyles JE, Williamson ED, Spier ID, Alpar HO. Protection studies following bronchopulmonary and intramuscular immunization with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine18, 3266–3271 (2000).
   PubMed Web of Science ®Google Scholar
• Griffin KF, Eyles JE, Spiers ID, Alpar HO, Williamson ED. Protection against plague following immunization with microencapsulated V antigen is reduced by co-encapsulation with IFN-γ or IL-4, but not IL-6. Vaccine20, 3650–3657 (2002).
   PubMed Web of Science ®Google Scholar
• Baca-Estrada ME, Foldvari MM, Snider MM, Harding KK, Kournikakis BB, Griebel PP. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine18, 2203–2211 (2000).
   PubMed Web of Science ®Google Scholar
• Heath DG, Anderson GW Jr, Mauro JM et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1–V antigen fusion protein vaccine. Vaccine16(11–12), 1131–1137 (1998).
   PubMed Web of Science ®Google Scholar
• Powell BS, Andrews GP, Enama JT et al. Design and testing for a nontagged F1–V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol. Prog.21(5), 1490–1510 (2005).
   PubMed Web of Science ®Google Scholar
• Jones T, Adamovicz JJ, Cyr SL et al. Intranasal protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine24(10), 1625–1632 (2006).
   PubMed Web of Science ®Google Scholar
• Glynn A, Roy CJ, Powell BS, Adamovicz JJ, Freytag LC, Clements JD. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime–boost with recombinant plague antigens. Infect. Immun.73(8), 5256–5261 (2005).
   PubMed Web of Science ®Google Scholar
• Amemiya K, Meyers JL, Rogers TE et al. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine27(16), 2220–2229 (2009).
   PubMed Web of Science ®Google Scholar
• Kummer LW, Szaba FM, Parent MA et al. Antibodies and cytokines independently protect against pneumonic plague. Vaccine26(52), 6901–6907 (2008).
   PubMed Web of Science ®Google Scholar
• Morton M, Galmory HS, Perkins SD et al. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine22, 2524–2532 (2004).
   PubMed Web of Science ®Google Scholar
• Oyston PCF, Williamson ED, Leary SEC, Eley SM, Griffin KF, Titball RW. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect. Immun.63, 563–568 (1995).
   PubMed Web of Science ®Google Scholar
• Simpson WJ, Thomas RE, Schwan TG. Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. Am. J. Trop. Med. Hyg.43, 389–396 (1990).
   PubMed Web of Science ®Google Scholar
• Gremiakova TA, Amel’chenko VA, Anisimov AP. Early protection of animals immunized by a recombinant plague vaccine from experimental plague. Bull. Eksp. Biol. Med.119, 54–57 (1995).
   Google Scholar
• Cleri DJ, Vernaleo JR, Lombardi LJ et al. Plague pneumonia disease caused by Yersinia pestis. Semin. Respir. Infect.12(1), 12–23 (1997).
   PubMedGoogle Scholar
• Leary SE, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun.63, 2854–2858 (1995).
   PubMed Web of Science ®Google Scholar
• Motin VL, Nedialkov YuA, Brubaker RR. V antigen–polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Infect. Immun.64, 4313–4318 (1996).
   PubMed Web of Science ®Google Scholar
• Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog.23, 167–178 (1997).
   PubMed Web of Science ®Google Scholar
• Daniel C, Sebbane F, Poiret S et al. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV. Vaccine27, 1141–1144 (2009).
   PubMed Web of Science ®Google Scholar
• Do Y, Park CG, Kang YS et al. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur. J. Immunol.38, 20–29 (2008).
   PubMed Web of Science ®Google Scholar
• Wang S, Heilman D, Liu F et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine22, 3348–3357 (2004).
   PubMed Web of Science ®Google Scholar
• Wang S, Joshi S, Mboudjeka I et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/c mice. Vaccine26, 1664–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Hoyt T, Bowen R et al. An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague. Vaccine27, 80–87 (2009).
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Hoyt T, Yang X et al. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1–V fusion protein confers protection against pneumonic plague. Infect. Immun.76, 4564–4573 (2008).
   PubMed Web of Science ®Google Scholar
• Garmory HS, Freeman D, Brown KA, Titball RW. Protection against plague afforded by immunization with DNA vaccines optimized for expression of the Yersinia pestis V antigen. Vaccine22, 947–957 (2004).
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Biological Standardisation 2005/BS/05.2013 Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines. In: WHO Expert Commitee on Biological Standardization: 56th Report. WHO, Geneva, Switzerland, 20–21 (2007).
   Google Scholar
• Dalvadyants SM, Dubrovin MYu, Byvalov AA et al. A study of immunization against plague. Communication 3. Revaccination properties of the plague vaccine and the preparations of plague chemical vaccines for Hamadryas baboons. In: Problems of Particularly Dangerous Infections. Saratov, Russia, 89, 62–67 (2005).
   Google Scholar
• Corbel MJ. The regulatory control and quality assurance of immunological products. Section S2. In: Industrial Pharmaceutical Microbiology. Euromed Communications Ltd, Haslemere, UK, S2.1–S2.16 (2004).
   Google Scholar
• Williamson ED, Flick-Smith HC, Waters E et al. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb. Pathog.42(1), 11–21 (2007).
   PubMed Web of Science ®Google Scholar
• Zauberman A, Cohen S, Levy Y et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine26(13), 1616–1625 (2008).
   PubMed Web of Science ®Google Scholar
• Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect. Immun.71(4), 2234–2238 (2003).
   Google Scholar